首页> 外文期刊>Expert opinion on therapeutic targets >Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin.
【24h】

Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin.

机译:新型因素作为治疗糖尿病的治疗靶标。专注于瘦素和生长素释放肽。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Obesity is the major cause of type 2 diabetes. In the mid 1990s interest in adipose tissue was revived by the discovery of leptin. The association of obesity and diabetes emphasizes their shared physiopathological features. At the end of the 1990s, ghrelin, a potent gastric orexigenic factor, was found to be involved in obesity. Leptin and ghrelin have opposite actions in several tissues including the regulation of feeding in the brain. OBJECTIVE/METHODS: To survey the role of leptin and ghrelin in glucose metabolism. We summarize the current state of research and discuss the roles of ghrelin and leptin in glucose homeostases and the potential application of drugs targeting leptin and ghrelin signalling to prevent and treat diabetes. RESULTS/CONCLUSIONS: A pressing challenge is to determine how leptin, ghrelin and other adipokines or gastric factors are involved in metabolic disorders. Answering these questions will require the development of new pharmacological tools that target specific adipokine systems. Hopefully, new therapeutic targets will be identified.
机译:背景:肥胖是2型糖尿病的主要原因。在1990年代中期,瘦素的发现使人们对脂肪组织的兴趣恢复了。肥胖与糖尿病的关系强调了它们共同的生理病理特征。在1990年代末,发现ghrelin是一种有效的胃致癌因素,与肥胖有关。瘦素和生长素释放肽在几种组织中具有相反的作用,包括调节大脑的进食。目的/方法:研究瘦素和生长素释放肽在葡萄糖代谢中的作用。我们总结了目前的研究现状,并讨论了ghrelin和leptin在葡萄糖稳态酶中的作用以及靶向leptin和ghrelin信号的药物在预防和治疗糖尿病中的潜在应用。结果/结论:一项紧迫的挑战是确定瘦素,生长素释放肽和其他脂肪因子或胃因子如何参与代谢性疾病。要回答这些问题,就需要开发针对特定脂肪因子系统的新药理学工具。希望将确定新的治疗靶标。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号